NYSEAMERICAN : CVM
CEL-SCI Corporation — Key statistics
Healthcare · Biotechnology · United States
Last price 1.45 USD (Oct 30, 2026, 9:39 AM EDT) · Market cap 25.50M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 24.27M |
| Enterprise Value | 25.64M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 13, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 17.59M |
| Shares Outstanding | 17.59M |
| Shares Change (YoY) | +215.73% |
| Shares Change (QoQ) | +48.88% |
| Owned by Insiders (%) | 3.79% |
| Owned by Institutions (%) | 14.59% |
| Float | 16.92M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 2.22 |
| P/TBV Ratio | 2.23 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 1.48 |
| Quick Ratio | 1.29 |
| Debt / Equity | 0.72 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -50.19 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -252.53% |
| Return on Assets (ROA) | -66.82% |
| Return on Invested Capital (ROIC) | -77.72% |
| Return on Capital Employed (ROCE) | -136.92% |
| Weighted Average Cost of Capital (WACC) | 6.74% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$515,991 |
| Employee Count | 44 |
| Asset Turnover | n/a |
| Inventory Turnover | 37.71 |
Taxes
| Measure | Value |
|---|
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 0.59 |
| 52-Week Price Change | -81.82% |
| 50-Day Moving Average | 1.70 |
| 200-Day Moving Average | 2.52 |
| Relative Strength Index (RSI) | 35.95 |
| Average Volume (20 Days) | 231,198 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 663,833 |
| Short Previous Month | 619,262 |
| Short % of Shares Out | 3.77% |
| Short % of Float | 3.92% |
| Short Ratio (days to cover) | 2.46 |
Incomestatement
| Measure | Value |
|---|
| Revenue | n/a |
| Gross Profit | -14.80M |
| Operating Income | -22.29M |
| Pretax Income | -22.70M |
| Net Income | -22.70M |
| EBITDA | -20.26M |
| EBIT | -22.29M |
| Earnings Per Share (EPS) | -$2.57 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 6.54M |
| Total Debt | 7.90M |
| Net Cash | -1.36M |
| Net Cash Per Share | -$0.08 |
| Equity (Book Value) | 10.96M |
| Book Value Per Share | 0.62 |
| Working Capital | 2.42M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -16.75M |
| Capital Expenditures | -5,155 |
| Depreciation & Amortization | 2.03M |
| Net Borrowing | -2.21M |
| Free Cash Flow | -16.75M |
| FCF Per Share | -$0.95 |
Margins
| Measure | Value |
|---|
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -215.73% |
| Shareholder Yield | -215.73% |
| Earnings Yield | -186.15% |
| FCF Yield | -69.01% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $12.50 |
| Price Target Difference | 805.80% |
| Analyst Consensus | Buy |
| Analyst Count | 2 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | May 20, 2025 |
| Split Type | Reverse |
| Split Ratio | 1:30 |
Scores
| Measure | Value |
|---|
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |